velsera
Accelerates precision medicine with AI-driven software and data insights.
Company facts
- Founded
- 2022
- Employees
- 428
- Headquarters
- United States
- CEO
- Jamie Littlejohns
- Type
- Private
- Funding
- Private Equity · 2023
- Subsidiaries
- Seven Bridges, Pierian, UgenTec
About
What started in the healthcare landscape as a vision for transforming how genetic data can enhance precision medicine has grown into Velsera, a trailblazing Health Tech company. Officially founded in 2022 through a merger of industry pioneers like Pierian, Seven Bridges, and UgenTec, Velsera aims to bridge the gap between clinical diagnostics and innovative discovery. With a passionate team dedicated to pushing the boundaries of research and assisting healthcare professionals, Velsera has rapidly evolved its product offerings, focusing on data analytics and behavioral science. At the heart of our mission is a commitment to accelerate breakthroughs in clinical diagnostics and precision medicine. Velsera uniquely combines advanced software enabled by expert services to streamline the entire process of discovering, developing, and delivering impactful health solutions. From technical partnerships with clinical diagnostic labs to collaborative efforts with biotech companies, our integrated software enables faster genetic testing, enhances data utility, and ultimately improves patient outcomes. By harmonizing data across diverse platforms and ensuring compliance with evolving regulations, Velsera empowers researchers and healthcare providers to unlock the true potential of multi-omic insights and drive innovation globally.